^
CANCER:

Anaplastic Astrocytoma

Related cancers:
No biomarker
Anaplastic Astrocytoma
temozolomide
Sensitive: A1 - Approval
No biomarker
Anaplastic Astrocytoma
PCV
Sensitive: A2 - Guideline
IDH1 R132H
Anaplastic Astrocytoma
temozolomide
Sensitive: B - Late Trials
MGMT promoter methylation
Anaplastic Astrocytoma
temozolomide
Sensitive: B - Late Trials
BRAF V600
Anaplastic Astrocytoma
vemurafenib
Sensitive: C1 - Off-label
NRAS mutation
Anaplastic Astrocytoma
atezolizumab + cobimetinib
Sensitive: C3 – Early Trials
IDH2 mutation
Anaplastic Astrocytoma
PCV
Sensitive: C3 – Early Trials
IDH1 mutation
Anaplastic Astrocytoma
PCV
Sensitive: C3 – Early Trials
ABCB1 G412G
Anaplastic Astrocytoma
temozolomide
Sensitive: C3 – Early Trials
TMB-H
Anaplastic Astrocytoma
nivolumab
Sensitive: C3 – Early Trials
NACC2-NTRK2 fusion
Anaplastic Astrocytoma
larotrectinib
Sensitive: C4 – Case Studies
IDH1 R132S + H3K27me3 loss + MET exon 14 skipping mutation
Anaplastic Astrocytoma
carboplatin + temozolomide + vincristine
Resistant: C4 – Case Studies
BRAF mutation
Anaplastic Astrocytoma
dabrafenib
Sensitive: C4 – Case Studies